4 Jul 2013 11:22
4 July 2013
Omega Diagnostics Group PLC
("Omega" or the "Company")
Grant of Options
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that further to its announcement on 22 April 2013 concerning the appointment of Bill Rhodes as a director of the Company, including an obligation to be granted an option over 2,130,406 ordinary shares of the Company at the prevailing market price at the earliest opportunity, its Remuneration Committee has today confirmed the award of the share options at an exercise price of 15.25p, being the closing mid-market price on 3 July 2013. Following the grant, these options represent Bill Rhodes' only interest in the Company.
The options have been awarded under the Company's Third Unapproved Option Scheme with one third of the options vesting equally over the first, second and third anniversary of the date of grant.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 |
Andrew Shepherd, Chief Executive | www.omegadiagnostics.com |
Kieron Harbinson, Group Finance Director | |
Jag Grewal, Group Sales and Marketing Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Christopher Raggett (Corporate Finance) | |
Stephen Norcross/Mia Gardner (Corporate Broking) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |